Litcius/Paper detail

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays

Andrea Padoan, Chiara Cosma, Francesco Bonfante, Foscarina Della Rocca, Francesco Barbaro, Claudia Santarossa, Luigi Dall’Olmo, Matteo Pagliari, Alessio Bortolami, Anna Maria Cattelan, Vito Cianci, Daniela Basso, Mario Plebani

2021Clinica Chimica Acta26 citationsDOIOpen Access PDF

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ChemiluminescenceVirologyAntibodyCoronavirus disease 2019 (COVID-19)MedicineChemistryImmunologyInternal medicineChromatographyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing
SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays | Litcius